Stock of Second Sight Medical Inc. (NASDAQ: EYES) is soaring high since the company has got approval from US Food and Drug Administration FDA for Argus 2s Retinal Prosthesis System which is being developed to treat Retinitis Pigmentosa (RP).  The company is known for manufacturing and marketing implantable visual prosthetics for blind individuals to give them an artificial vision. The company has dedicated its services towards developing efficient technologies for sight impaired individuals.

Recent Developments

The Argus 2s Retinal Prosthesis system is an improvised version of external hardware used alongside its Argus II implant. The system basically has a pair of glasses and a camera that functions to provide vision to the people diagnosed with retinitis pigmentosa (RP). In company’s future plans they are hoping to use the Argus 2s Retinal Prosthesis System in the next generation of Orion Visual Cortical Prosthesis System which is an under development system for the treatment of RP. 

The company claims that this new system for the treatment of RP has many different and improved specifications compared to its predecessor which includes

• Improved ergonomics
• Powerful processing power, which means that video processing will get better.

To better understand the reliability of this system, we should know that how it works. Argus 2s provides electrical stimulation that bypass the deteriorating retinal cells and further stimulate the viable cells which are left, including visual perception in individuals with chronic or mild cases of RP.

EYES stock surpassed every other company and became the most traded stock after the FDA approval. The trading volume increased to 222.6 shares compared to an average of 26.5 million shares in a day. Furthermore, the CEO of the company said that they are humbled to receive this approval since this opportunity will play a vital role in enhancing company’s efforts towards facilitating those with no vision.

Conclusion

This system introduced by the company will definitely call the interest of investors towards it. The efficiency of the system will give a boost to the company’s stock and will help them to develop a more modified version.